RxDoctor Payments Data

Ashley Daniels

Primary Care · Clinton, NCNPI 1972365039

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 40 payments — averaging $28.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$607
  • Novo Nordisk$267
  • Lilly USA, LLC$74
  • AbbVie$60
  • ANI Pharmaceuticals, Inc.$40
  • Exact Sciences$40
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$1,122100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,122 in reported general payments places this provider in the 70th percentile of 236 primary care providers in North Carolina.

See all primary care providers in North Carolina

Medicare billing

Part B allowed, 2024
$10,991
Medicare patients
70
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$32,075
MounjaroTirzepatide25$26,358
EliquisApixaban24$21,914
Nurtec OdtRimegepant Sulfate11$21,019
RybelsusSemaglutide11$19,875
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,214
LinzessLinaclotide17$10,324
Celecoxib25$1,067
Atorvastatin Calcium127$962
Albuterol Sulfate HfaAlbuterol Sulfate44$931
Amlodipine Besylate102$837
Bupropion XlBupropion Hcl19$817
Omeprazole61$808
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$707
Gabapentin69$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$267$51,95035 claims
Lilly USA, LLCMounjaro$74$26,35825 claims
AbbVieLinzess$60$10,32417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 236 primary care providers in North Carolina.

Other primary care in Clinton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →